4/29
07:00 am
ntla
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Medium
Report
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
4/28
02:34 pm
ntla
Intellia Therapeutics (NTLA) had its price target raised by Canaccord Genuity Group Inc. from $48.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Intellia Therapeutics (NTLA) had its price target raised by Canaccord Genuity Group Inc. from $48.00 to $58.00. They now have a "buy" rating on the stock.
4/28
10:25 am
ntla
Intellia Therapeutics (NTLA) had its price target raised by Citizens Jmp from $28.00 to $30.00. They now have a "market outperform" rating on the stock.
Low
Report
Intellia Therapeutics (NTLA) had its price target raised by Citizens Jmp from $28.00 to $30.00. They now have a "market outperform" rating on the stock.
4/28
08:00 am
ntla
Intellia Therapeutics (NTLA) had its "sell" rating reaffirmed by The Goldman Sachs Group, Inc..
Low
Report
Intellia Therapeutics (NTLA) had its "sell" rating reaffirmed by The Goldman Sachs Group, Inc..
4/28
07:28 am
ntla
Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt [Seeking Alpha]
Low
Report
Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt [Seeking Alpha]
4/28
07:00 am
ntla
Intellia Therapeutics (NTLA) had its "outperform" rating reaffirmed by Citigroup Inc..
Low
Report
Intellia Therapeutics (NTLA) had its "outperform" rating reaffirmed by Citigroup Inc..
4/27
09:22 pm
ntla
Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing [Yahoo! Finance]
Low
Report
Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing [Yahoo! Finance]
4/27
09:12 pm
ntla
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? [Yahoo! Finance]
Low
Report
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? [Yahoo! Finance]
4/27
04:28 pm
ntla
Intellia Therapeutics launches $150M public stock offering [Seeking Alpha]
Medium
Report
Intellia Therapeutics launches $150M public stock offering [Seeking Alpha]
4/27
04:01 pm
ntla
Intellia Announces Proposed Public Offering of Common Stock
Medium
Report
Intellia Announces Proposed Public Offering of Common Stock
4/27
03:54 pm
ntla
Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data [Yahoo! Finance]
Low
Report
Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data [Yahoo! Finance]
4/27
03:00 pm
ntla
Intellia Therapeutics (NTLA) was given a new $35.00 price target by Leerink Partners.
Low
Report
Intellia Therapeutics (NTLA) was given a new $35.00 price target by Leerink Partners.
4/27
03:00 pm
ntla
Intellia Therapeutics (NTLA) was given a new $15.00 price target by Morgan Stanley.
Low
Report
Intellia Therapeutics (NTLA) was given a new $15.00 price target by Morgan Stanley.
4/27
02:28 pm
ntla
Intellia Therapeutics (NTLA) had its price target raised by Chardan Capital from $27.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Intellia Therapeutics (NTLA) had its price target raised by Chardan Capital from $27.00 to $30.00. They now have a "buy" rating on the stock.
4/27
02:28 pm
ntla
Intellia Therapeutics (NTLA) had its price target raised by Robert W. Baird from $7.00 to $13.00. They now have a "neutral" rating on the stock.
Medium
Report
Intellia Therapeutics (NTLA) had its price target raised by Robert W. Baird from $7.00 to $13.00. They now have a "neutral" rating on the stock.
4/27
09:03 am
ntla
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema [Yahoo! Finance]
Medium
Report
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema [Yahoo! Finance]
4/27
07:14 am
ntla
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing [Yahoo! Finance]
Low
Report
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing [Yahoo! Finance]
4/27
07:02 am
ntla
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial [CNBC]
Medium
Report
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial [CNBC]
4/27
07:00 am
ntla
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
High
Report
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
4/27
07:00 am
ntla
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
High
Report
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
4/24
04:28 pm
ntla
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 [Yahoo! Finance]
High
Report
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 [Yahoo! Finance]
4/24
04:05 pm
ntla
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Medium
Report
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
4/15
05:25 pm
ntla
2 Healthcare Stocks to Buy and 1 to Approach With Caution [Globe and Mail, The (Toronto, Canada)]
Medium
Report
2 Healthcare Stocks to Buy and 1 to Approach With Caution [Globe and Mail, The (Toronto, Canada)]
4/3
04:05 pm
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/26
05:49 am
ntla
Intellia Therapeutics (NTLA) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Intellia Therapeutics (NTLA) was upgraded by Truist Financial Corporation to "strong-buy".